Low-dose neuroleptic therapy and relapse in schizophrenia: Meta-analysis of randomized controlled trials
Low-dose neuroleptic therapy and relapse in schizophrenia: Meta-analysis of randomized controlled trials
复制标题
DOI：
10.1016/s0924-9338(96)89899-3
复制
发表时间：
1996-01-01
影响因子：
7.8
通讯作者：
Garattini, S
中科院分区：
文献类型：
--
作者：
Barbui, C;Saraceno, B;Garattini, S
我们评估了低剂量与标准剂量抗精神病药物治疗在降低精神分裂症患者复发率方面的相对疗效和有效性。通过MEDLINE检索检索到6项长期随机对照试验。与传统的200 - 500 mg剂量方案相比，50 - 100 mg剂量方案的氯丙嗪可增加慢性精神分裂症患者复发的可能性。然而，差异在治疗12个月时具有统计学显著性，但在治疗24个月时不具有统计学显著性。
We assessed the relative efficacy and effectiveness of low-versus standard-dose neuroleptic therapy in reducing relapse rate in schizophrenic patients. Six long-term randomized controlled trials were retrieved through a MEDLINE search. A dose regimen between 50 and 100 mg equivalent of chlorpromazine, compared to a conventional one between 200 and 500 mg, was found to increase the Likelihood of relapse in chronic schizophrenic patients. Differences, however, were statistically significant at 12 but not at 24 months of treatment.